Danaher Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Rainer Blair
- Full Time Employees
- 59,000
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 2200 Pennsylvania Avenue, NW Washington DC United States of America 20037-1701
- IPO Date
- Dec 29, 1978
- CIK
- 0000313616
- Website
- danaher.com
- Similar Companies
- Business
- Danaher Corporation (NYSE: DHR), founded in 1984 and headquartered in Washington, D.C., operates as a leading global science and technology innovator focused on life sciences and diagnostics. The company conducts business through three primary segments: biotechnology, which develops products and services for therapeutic development including bioprocessing solutions, plasmid DNA, mRNA, proteins, and genomic medicines via brands such as Cytiva, Aldevron, and Abcam; life sciences, offering instruments like mass spectrometers, flow cytometry systems, microscopes, genomics consumables, lab automation, centrifugation, particle characterization, and gene and cell therapy tools; and diagnostics, providing clinical instruments, reagents, consumables, software, and services for disease diagnosis in hospitals, physicians' offices, reference laboratories, and critical care settings through subsidiaries including Cepheid and Beckman Coulter. Danaher serves customers worldwide across biopharmaceutical, research, healthcare, and precision medicine markets, employing approximately 63,000 associates in over 125 countries. Recent developments include the 2023 acquisition of Abcam for proteomic research consumables to accelerate drug discovery; a January 2025 investment partnership with Innovaccer Inc. through Danaher Diagnostics LLC and Danaher Ventures LLC to advance AI-enabled diagnostics and precision medicine; and a May 2025 diagnostic development and commercialization alliance with AstraZeneca to scale next-generation AI-powered diagnostics solutions.
Company News
Danaher Schedules Third Quarter 2026 Earnings Conference Call
Nykredit A S Takes Position in Danaher Corporation $DHR
Danaher Announces Quarterly Dividend
ELV or DHR: Which Is the Better Value Stock Right Now?
Bank of America Corp DE Makes New Investment in Danaher Corporation $DHR
Danaher Corporation $DHR Shares Acquired by Concurrent Investment Advisors LLC
Continuum Advisory LLC Decreases Holdings in Danaher Corporation $DHR
Danaher Corporation $DHR Shares Sold by HB Wealth Management LLC
Why Moderna's Cancer Vaccine Matters to Investors
Ausdal Financial Partners Inc. Buys Shares of 2,452 Danaher Corporation $DHR
315,789 Shares in Danaher Corporation $DHR Purchased by Bamco Inc. NY
Danaher Rides on Strength in Biotechnology Segment: Will It Sustain?
Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.
Ally Financial Inc. Invests $8.95 Million in Danaher Corporation $DHR
Callan Family Office LLC Buys Shares of 4,198 Danaher Corporation $DHR
Advisors Capital Management LLC Buys New Shares in Danaher Corporation $DHR
Allworth Financial LP Invests $57.02 Million in Danaher Corporation $DHR
11,176 Shares in Danaher Corporation $DHR Acquired by Allworth Financial LP
932,220 Shares in Danaher Corporation $DHR Bought by Bank of New York Mellon Corp
Bank of New York Mellon Corp Purchases New Position in Danaher Corporation $DHR